The US regulator has said that compounders can continue to trade in tirzepatide products while it undertakes a review to ...

Federal regulators shook up the booming weight loss drug marketplace when they announced Mounjaro and Zepbound to be no longer in shortage after nearly two years. Pharmacies that sold ...

There’s a war brewing over blockbuster weight loss medications — and patients are now getting caught in the crossfire.

The FDA decision will enable Antag Therapeutics to initiate the clinical development of its lead candidate drug, a ...

WW stock popped after announcing a new compounded semaglutide product to benefit from the current shortage of weight loss ...

PBMs are putting weight loss drugs, including Wegovy and Zepbound, on their national formularies, but coverage by plans is ...

Newly released data shows that the U.S. may have reached peak obesity in 2020 — and the timing unsurprisingly coincides with ...

After psychological side effects doomed the first generation of cannabinoid receptor 1–targeting drugs for weight loss, Novo ...

The FDA updated its database of drugs in shortage to remove tirzepatide, which had sat on that list – along with related ...

Eli Lilly’s juggernaut diabetes and obesity drugs Mounjaro and Zepbound have been erased from the FDA’s shortage list, ...

The group represents makers of compounded versions of drugs that benefit from shortages of branded FDA-approved medications like tirzepatide and Novo's (NVO) rival weight loss therapy, semaglutide.

After nearly two years, federal regulators announced the shortage of the active ingredient in Mounjaro and Zepbound has been ...